| Pre-Congress,
9-11 July (Friday - Sunday) |
|
APLAR Musculoskeletal
Ultrasound Course in Rheumatology
(Additional registration fee is required) |
|
Course
Information |
|
| |
|
| Day
1, 11 July (Sunday) |
|
| 0900-1630 |
ACR
Review Course for Clinicians (Free for full and day delegates) |
|
| |
Chairpersons:
Dr. Cheuk Wan YIM (Hong Kong) & Dr.
Man Leung KWOK (Hong Kong)
|
|
| 0900-1000 |
ACR-1
- Osteoarthritis: New Thoughts on an Old Disease |
Prof.
Joel A BLOCK (USA) |
|
| 1000-1100 |
ACR-2
- Drug Therapy for Rheumatic Diseases in the Elderly |
Prof.
Raymond YUNG (USA) |
|
| 1100-1200 |
ACR-3
- Rheumatology's Target Organ: Joint Biology and Prospects
for Repair |
Prof.
Joel A BLOCK (USA) |
|
| 1200-1330 |
Lunch |
|
|
| 1330-1430 |
ACR-4
- An Update on Rheumatoid Arthritis Treatments: the
Present and Future |
Prof.
Stanley B COHEN (USA) |
|
| 1430-1530 |
ACR-5
- Drug-induced Lupus: An Update |
Prof.
Raymond YUNG (USA) |
|
| 1530-1630 |
ACR-6
- Glucocorticoid Induced Bone Loss: Impact of the New
ACR Guidelines on Diagnosis and Management |
Prof.
Stanley B COHEN (USA) |
|
| |
|
|
| 0900-1630 |
APLAR
Basic Science Review Course (Free for full and day delegates) |
|
| 0900-1015 |
The
innate immune system and autoimmunity |
|
| |
Chairperson:
Prof. Ranjeny THOMAS (Australia)
|
|
| 0900-0935 |
BSRC-1.1
- Dendritic cell |
Prof.
Ranjeny THOMAS (Australia) |
|
| 0935-1010 |
BSRC-1.2
- Toll-like Receptors and Innate Immunity |
Prof.
Eddy F Y LIEW (UK) |
|
| 1000-1045 |
Coffee
Break |
|
|
| 1045-1200 |
T
cells and autoimmunity |
|
|
| |
Chairperson:
Dr. Temy Mo Yin MOK
(Hong Kong) |
|
|
| 1045-1120 |
BSRC-2.1-
TH17 cells |
Prof.
Wim B VAN DEN BERG (The Netherlands) |
|
| 1120-1155 |
BSRC-2.2
- Treg cells |
Prof.
Shimon SAKAGUCHI (Japan) |
|
| 1155-1330 |
Lunch |
|
|
| 1330-1445 |
B
cells, cytokines and autoimmunity |
|
|
| |
Chairperson:
Dr. Liwei LU (Hong Kong)
|
|
|
| 1330-1405 |
BSRC-3.1
- Role of B cell-activating factor in autoimmune arthritis
|
Dr.
Liwei LU (Hong Kong) |
|
| 1405-1440 |
BSRC-3.2
- Novel cytokines |
Prof.
Peter E LIPSKY (USA) |
|
| 1440-1515 |
Coffee
Break |
|
|
| |
Immunology
beyond autoimmune disease |
|
|
| |
Chairperson:
Prof. Nan SHEN (China) |
|
|
| 1515-1550 |
BSRC-4.1
- Osteoimmunology |
Prof.
Hiroshi TAKAYANAGI (Japan) |
|
| 1550-1625 |
BSRC-4.2
- Proteomics, transcriptomics and epigenetics |
Prof.
Steffen GAY (Switzerland) |
|
| 1700-1730 |
Opening
Ceremony |
|
| 1730-1815 |
Keynote
Lecture
Chairperson: Dr. Tak Hin CHAN (Hong
Kong)
Excellence in Medicine and Rheumatology-Enter
the Dragon! |
Prof.
Chak Sing LAU (Hong Kong) |
|
| 1815-2000 |
Welcome
Reception (Free for full
delegates) |
|
| |
|
| Day
2, 12 July (Monday) |
|
| 0830-1000 |
Plenary
Session 1 : Rheumatoid Arthritis (RA) |
|
| |
Chairpersons:
Prof. Pao Hsii FENG (Singapore) &
Dr. Raymond WONG (Hong Kong)
|
|
| 0830-0900 |
Plenary
1-1 - Pathogenesis of Rheumatoid arthritis : New insights
into Autoimmunity by Th17 related Cytokines |
Prof.
Ho-Youn KIM (Korea) |
|
| 0900-0930 |
Plenary
1-2 - Is remission possible in RA? |
Prof.
Ferdinand C BREEDVELD (The Netherlands) |
|
| 0930-1000 |
Plenary
1-3- Biologics in RA |
Prof.
Paul EMERY (UK) |
|
| 1000-1010 |
Young
Investigator Awards Presentation & Launch of ¡§Every
Day Counts¡¨ Program |
|
| 1010-1100 |
Poster
Viewing |
|
| 1100-1230 |
Concurrent
Symposia 1 |
|
| ¡@ |
CS1:
EULAR symposium on management of early RA |
¡@ |
|
| |
Chairpersons:
Prof. Rohini HANDA (India) & Dr.
Shirley YING (Hong Kong)
|
|
| 1100-1130 |
CS1-1
- Treating Rheumatoid Arthritis to target |
Prof.
Josef S SMOLEN (Austria) |
|
| 1130-1200 |
CS1-2
- The Armamentarium of Therapy for Rheumatoid Arthritis |
Prof.
Paul EMERY (UK) |
|
| 1200-1230 |
CS1-3
- Therapeutic Strategy in Rheumatoid Arthritis |
Prof.
Ferdinand C BREEDVELD (The Netherlands)
|
|
| ¡@ |
CS2:
Imaging in rheumatology I |
¡@ |
|
| |
Chairpersons:
Dr. George BRUYN (Netherlands) &
Dr. Violet K L LEE (Hong Kong)
|
|
| 1100-1130 |
CS2-1
- Usefulness of modern USG in the assessment and treatment
of RA |
Prof.
Richard WAKEFIELD (UK)
|
|
| 1130-1200 |
CS2-2 - Application
of USG in SpA |
Prof.
Peter BALINT (Hungary)
|
|
| 1200-1230 |
CS2-3
- The role of PET in rheumatology |
Dr.
Frankie Pak Tat CHOI (Hong Kong)
|
|
| ¡@ |
BS1:
Regulatory T cells in rheumatic diseases |
¡@ |
|
| |
Chairpersons:
Prof. Wim B VAN DEN BERG (Germany)
& Prof. Fengchun ZHANG (China)
|
|
| 1100-1130 |
BS1-1
- Yin and Yang regulation of autoreactive T cells in
human autoimmune disease |
Dr.
Taylor Bingshi GUO (China)
|
|
| 1130-1200 |
BS1-2
- Inducing regulatory cells to control autoimmunity
- the role of Treg cells |
Prof.
Bevra HAHN (USA)
|
|
| 1200-1230 |
BS1-3
- Th17 and Treg in inflammatory diseases |
Prof.
Shimon SAKAGUCHI (Japan) |
|
| ¡@ |
PS1:
JIA, SLE and Vasculitis |
¡@ |
|
| |
Chairpersons:
Dr. P MANNERS (Australia) & Prof.
Y L LAU (Hong Kong)
|
|
| 1100-1130 |
PS1-1
- Genetics and biologic therapies in JIA |
Prof.
Patricia WOO (UK)
|
|
| 1130-1200 |
PS1-2
- Pediatric Lupus ¡V Are There Differences in Presentation,
Genetics, Response to Therapy, Damage Accrual Compared
to Adult Lupus? |
Dr.
HermineBRUNNER (USA) |
|
| 1200-1210 |
PS1-3
- [0019] Inherited rheumatic disorders in Saudi
|
SM
AL-MAYOUF/ SULAIMAN
(Saudi Arabia)
|
|
|
1210-1220 |
PS1-4
- [0296] Outcome of Kawasaki Disease patients treated
with intravenous methylprednisolone
|
CB
BERNAL (Philippines)
|
|
| 1220-1230 |
PS1-5
- [0670] Clinical, radiographic, and genetic diagnosis
of progressive pseudorheumatoid dysplasia in a case
with literature review
|
Wen ZHANG (China)
|
|
| ¡@ |
Free
paper presentation 1
Chairpersons: Prof. Dae-Hyun YOO
(Korea) & Prof. Nan SHEN (China) |
|
|
1100-1110 |
FP1-1
- [0693] Association of a functional IRF7 variant with
systemic lupus erythematosus
|
Q
FU (China)
|
|
| 1110-1120 |
FP1-2
- [0421] Specific anti-moesin antibodies: could it be
a novel biomarker of pulmonary involvement associated
with systemic sclerosis?
|
JL
ZHAO (China)
|
|
| 1120-1130 |
FP1-3
- [0882] Programmed Death-1 (PD-1) expression controls
suppressive CD8+ T cells in (New Zealand Black x New
Zealand White) F1 lupus-prone mice.
|
M
WONG (USA)
|
|
| 1130-1140 |
FP1-4
- [0423] Thalidomide has a therapeutic effect on interstitial
lung brosis:evidence from in vitro and in vivo studies
|
Yang
LI (China)
|
|
| 1140-1150 |
FP1-5
- [0505] Expression of SSA antigen epitopes in minor
salivary glands from patients with primary Sjogren's
syndrome
|
Hongbin
LI (China)
|
|
| 1150-1200 |
FP1-6
- [0237] Autoantibodies to REG, a regeneration factor,
in patients with primary Sjogren syndrome
|
Kiyomi
YOSHIMOTO (Japan)
|
|
| 1200-1210 |
FP1-7
- [0231] Interferon-£\ priming promotes macrophage-derived
foam cell formation: a novel link between interferon-£\
and atherosclerosis in Systemic lupus erythematosus
|
J
LI (China)
|
|
| 1210-1220 |
FP1-8
- [0554] Studies on the function of plasmacytoid dendritic
cells in healthy and systemic lupus erythematosus
|
Ou
JIN (China)
|
|
| 1220-1230 |
FP1-9
- [0063] Correlation of th17 and treg with clinical
parameters in patients with systemic sclerosis
|
N
JIANG (China)
|
|
| 1230-1400 |
Lunch
Symposium (Sponsored by
Roche)
The era of IL-6 receptor inhibition: What¡¦s on the RA
treatment horizon
Chairman: Prof. Josef S SMOLEN (Austria)
|
|
| 1235-1255 |
LS1-1
- IL-6 receptor inhibition and tocilizumab clinical
efficacy: Rationale and supporting evidence |
Prof.
Ernest CHOY (UK) |
|
| 1255-1320 |
S1-2
- Key efficacy features of tocilizumab in RA:
From clinical trials to treating patients in practice
|
Prof.
Edmund K LI (Hong Kong) |
|
| 1320-1345 |
LS1-3
- Safety and clinical management:
Core studies, long term extension and beyond
|
Prof.
Josef S SMOLEN (Austria) |
|
| 1400-1530 |
Concurrent
Symposia 2 |
|
| ¡@ |
CS3:
SLE - Lupus nephritis management forum |
¡@ |
|
| |
Chairpersons:
Dr. Caroline G ARROYO (Philippines)
& Dr. C C MOK (Hong Kong)
|
|
| 1400-1405 |
CS3
- Case study 1 - a patient with diffuse lupus nephritis
(class IVG) with impaired renal function |
Dr.
Chi Hung TO (Hong Kong) |
|
| 1405-1420 |
CS3-1
- Lupus Nephritis ¡V Choice of Initial Treatment: MMF
versus CYC
|
Prof.
Tak Mao CHAN (Hong Kong) |
|
| 1420-1425 |
CS3
- Case study 2 - progress of the patient |
Dr.
Chi Hung TO (Hong Kong) |
|
| 1420-1435 |
CS3-2
- Maintenance therapy in lupus nephritis ¡V why, which
agent, for whom and for how long?
|
Dr.
Chi Chiu MOK (Hong Kong) |
|
| 1435-1440 |
CS3
- Case Study 3 - a patient with refractory lupus nephritis
¡V persistent proteinuria and slowly deteriorating renal
function |
Dr.
Chi Hung TO (Hong Kong) |
|
| 1440-1455 |
CS3-3
- Treatment options for refractory lupus nephritis:
role of the calcineurin inhibitors and B cell depletion
therapies |
Prof.
Niansheng YANG (China) |
|
| 1455-1500 |
CS3
- Case Study 4 - a patient with pure membranous lupus
nephropathy |
Dr.
Chi Hung TO (Hong Kong) |
|
| 1500-1515 |
CS3-4
- Management of pure membranous lupus nephropathy |
Prof.
Michelle A PETRI (USA) |
|
| 1515-1530 |
CS3-5
- Lupus Nephritis ¡V Novel Targeted Therapies for Lupus
Nephritis and Biomarkers
|
Prof.
Tak Mao CHAN (Hong Kong) |
|
| ¡@ |
CS4:
Scleroderma |
¡@ |
|
| |
Chairpersons:
Dr. VK KRISHNAM (India) & Dr.
Edward, Hor Ming LIU (Hong Kong)
|
|
| 1400-1430 |
CS4-1
- Scleroderma lung disease |
Prof.
Christopher P DENTON (UK) |
|
| 1430-1500 |
CS4-2
- Pulmonary Hypertension in Scleroderma |
Prof.
Peter NASH (Australia) |
|
| 1500-1530 |
CS4-3
- Management of GI manifestation in scleroderma |
Dr.
Justin Chi Yuen WU (Hong Kong) |
|
| ¡@ |
BS2:
Pathogenesis of rheumatoid arthritis |
¡@ |
|
| |
Chairpersons:
Prof. Zhanguo LI (China) & Prof.
Ranjeny THOMAS (Australia)
|
|
| 1400-1430 |
BS2-1
- Gene expression analysis of peripheral blood from
RA patients |
Prof.
Tsutomu TAKEUCHI (Japan) |
|
| 1430-1500 |
BS2-2
- Role of Placenta Growth Factor in Rheumatoid Inflammation |
Prof.
Wan-Uk KIM (Korea) |
|
| 1500-1530 |
BS2-3
- Role of regulatory B cells in autoimmune arthritis |
Dr.
Liwei LU (Hong Kong) |
|
| ¡@ |
AHS1:
Life style re-design and exercises for people with arthritis |
¡@ |
|
| |
Chairpersons:
Mr Simon WONG (Hong Kong) & Mrs.
Susan OLIVER (UK)
|
|
| 1400-1500 |
AHS1-1
- Exercise and other conservative management options
for individuals with osteoarthritis |
Prof.
Kim BENNELL (Australia) |
|
| 1500-1510 |
AHS1-2
- Orthotic intervention in rheumatoid diseases |
Dr.
Aaron LEUNG (Hong Kong) |
|
| 1510-1520 |
AHS1-3
- Management of Hand Problems of People with Rheumatoid
Arthritis ¡V Local Experiences from An Occupational Therapist's
Perspective
|
Ms.
Man Wah, Josephine WONG (Hong Kong) |
|
| 1520-1530 |
AHS1-4
- Clinical Tai Chi: Overseas and Local Experience |
Mr.
Wilfred KWOK (Hong Kong) |
|
| ¡@ |
Free
paper presentation 2
Chairpersons: Prof. Shunle CHEN
(China) & Dr. Emily KUN (Hong Kong) |
|
|
1400-1410 |
FP2-1
- [0145] Five-years of treatment with belimumab, a BLyS-Specific
inhibitor, in patients with Systemic Lupus Erythematosus
(SLE): long-term safety and efficacy analyses
|
M
PETRI (USA)
|
|
| 1410-1420 |
FP2-2
- [0281] Belimumab, a BLyS-Specific Inhibitor, Reduces
Disease Activity and Severe Flares in Seropositive Systemic
Lupus Erythematosus (SLE) Patients: BLISS-76 Study
|
M
PETRI (USA)
|
|
| 1420-1430 |
FP2-3
- [0027] Association of bone morphogenetic proteins
with spinal fusion in ankylosing spondylitis
|
HA
CHEN (Taiwan)
|
|
| 1430-1440 |
FP2-4
- [0306] Increased serum TWEAK levels in Psoriatic arthritis:
relationship with disease activity and matrix metalloproteinase-3
serum levels
|
LP
XIA (China)
|
|
| 1440-1450 |
FP2-5
- [0611] Familial risk of ankylosing spondylitis in
China
|
ZM
LIN (China)
|
|
|
1450-1500 |
FP2-6
- [0708] TNF-alpha blockade is associated with sustained
reduction of carotid intima-media thickness for patients
with active psoriatic arthritis- a 2 year study
|
LS
TAM (Hong Kong)
|
|
| 1500-1510 |
FP2-7
- [0850] The frequency of Romanus lesions and posterior
element lesions on the lumbar MRI in axial spondylarthritis
|
ML
XU (China)
|
|
| 1510-1520 |
FP2-8
- [0922] The effect of infliximab treatment on bone
turnover and bone mineral density in patients with active
Psoriatic Arthritis (PsA)
|
LY
HO (Hong Kong)
|
|
| |
FP2-9
- [0707] Reactivation of latent tuberculosis infection
in patients receiving anti TNF-£\ therapy, is it more
of a cause for concern in Arab patients?? |
MK
AL IZZI (United Arab Emirates) |
|
| 1530-1600 |
Coffee
Break |
|
| 1600-1730 |
Concurrent
Symposia 3 |
|
| ¡@ |
CS5:
Vasculitis update |
¡@ |
|
| |
Chairpersons:
Prof. Gooly M SAATOVA (Kyrgyz Republic) &
Dr. Chi Keung SUNG (Hong Kong)
|
|
| 1600-1630 |
CS5-1
- Update on the management of Behcet's disease |
Prof.
Fereydoun DAVATCHI (Iran) |
|
| 1630-1700 |
CS5-2
- Update on the diagnosis and management of large vessel
vasculitis |
Prof.
Wolfgang SCHMIDT (Germany) |
|
| 1700-1730 |
CS5-3
- Mesenteric vasculitis resulting in acute abdominal
pain in patients with systemic lupus erythematosus |
Prof.
Kyung-Su PARK (Korea) |
|
| ¡@ |
CS6:
Inflammatory myopathies |
¡@ |
|
| |
Chairpersons:
Dr. Swan Sim YEAP (Malaysia) &
Dr. Hing Sum TSUI (Hong Kong)
|
|
| 1600-1630 |
CS6-1
- An update on the assessment and treatment of inflammatory
myopathies |
Prof.
Ingrid LUNDBERG (Sweden) |
|
| 1630-1700 |
CS6-2
- Novel autoantibodies and their relationship with the
pathogenesis of inflammatory myopathies |
Dr.
Eric Yuk Tat CHAN (Hong Kong) |
|
| 1700-1730 |
CS6-3
- Imaging in inflammatory myopathy |
Dr.
Yik WONG (Hong Kong) |
|
| ¡@ |
BS3:
Cytokines and chemokines in rheumatic diseases |
¡@ |
|
| |
Chairpersons:
Prof. Xuan ZHANG (China) & Dr.
Lai Woo MAK (Hong Kong)
|
|
| 1600-1630 |
BS3-1
- Novel cytokines in inflammatory diseases |
Prof.
Eddy F Y LIEW (UK) |
|
| 1630-1700 |
BS3-2
- Pro-inflammatory cytokines in systemic lupus erythematosus
|
Dr.
Temy Mo Yin MOK (Hong Kong) |
|
| 1700-1730 |
BS3-3
- Chemokines in arthritis |
Dr.
Kichul SHIN (Korea) |
|
| ¡@ |
ES1:
Focus on research in the APLAR region |
¡@ |
|
| |
Chairpersons:
Prof. Sandra V NAVARRA (Philippines)
& Dr. Samson LEE (Hong Kong) |
|
| 1600-1630 |
ES1-1
- Conduct of successful clinical research in APLAR countries |
Prof.
Rohini HANDA (India) |
|
| 1630-1700 |
ES1-2
- Science and Art of Rheumatology : Acts of Creation |
Dr.
Prakash PISPATI (India) |
|
| ¡@ |
Free
Paper presentation 3
Chairpersons: Prof. Pao Hsii FENG
(Singapore) & Dr. Chi Hung TO (Hong
Kong) ¡@ |
|
|
1600-1610 |
FP3-1
- [0041] An introduction on Chinese registry of systemic
lupus erythematosus: preliminary data from CSTAR (Chinese
SLE Treatment and Research group)
|
MT
LI (China)
|
|
| 1610-1620 |
FP3-2
- [0100] A prospective evaluation of cognitive function
in patients with newly diagnosed Systemic Lupus Erythematosus
(SLE): Results of a pilot event-related functional Magnetic
Resonance Imaging (fMRI) study
|
A
MAK (Singapore)
|
|
| 1620-1630 |
FP3-3
- [0185] Association of elevated interferon-inducible
gene expressions with proatherosclerotic factors in
SLE patients
|
XB
FENG (China)
|
|
| 1630-1640 |
FP3-4
- [0643] Asymptomatic pulmonary hypertension in patients
with systemic lupus erythematosus
|
GI
CABASAN (Philippines)
|
|
| 1640-1650 |
FP3-5
- [0782] Mortality of hospitalized systemic lupus erythematosus
patients in China
|
LY
SUN (China)
|
|
| 1650-1700 |
FP3-6
- [0788] Seasonal variation in the incidence of disease
flares of systemic lupus erythematosus: II. relationship
between flares in individual organ systems and weather
parameters
|
CH
TO (Hong Kong)
|
|
| 1700-1710 |
FP3-7
- [0929] Effect of Systemic Lupus Erythematosus (SLE)
on pregnancy outcome: an analysis of 268 pregnancies
|
LY
HO (Hong Kong)
|
|
| 1710-1720 |
FP3-8
- [0106] Multicenter prospective study of evolution
and outcome of patients with recently diagnosed systemic
lupus erythematosus from Western India |
P
KHARBANDA (India) |
|
| 1720-1730 |
FP3-9
- [0937] Long term outcome of patients with Systemic
Lupus Erythematosus: data from a cross-sectional study
in Shanghai Renji Hospital Lupus Cohort
|
Shunle
CHEN (China)
|
|
| 1730-1830 |
Evening
Symposium (Sponsored by Bristol-Myers Squibb)
|
|
| |
Chairperson:
Prof. Edmund LI (Hong Kong) |
|
1732-1805
|
ES1-1
- Orencia mechanism of action, clinical trial efficacy
& safety summary
|
Prof.
Peter NASH (Australia)
|
|
1805-1815
|
ES1-2
- Japanese & Korean bridging studies
|
Prof.
Tsutomu TAKEUCHI (Japan)
|
|
| |
|
| Day
3, 13 July (Tuesday) |
|
| 0830-1000 |
Plenary
Session 2 : Osteoporosis |
¡@ |
|
| |
Chairpersons:
Prof. John EDMONDS (Australia) &
Dr. Anthony LEE (Hong Kong)
|
|
| 0830-0900 |
Plenary
2-1 - The epidemiology of osteoporosis in the Asia Pacific
region |
Dr.
Edith Ming Chu LAU (Hong Kong) |
|
| 0900-0930 |
Plenary
2-2 - Genetic and environmental determinants of osteoporosis |
Prof.
Annie Wai Chee KUNG (Hong Kong) |
|
| 0930-1000 |
Plenary
2-3 - Update on the treatment of osteoporotic fractures |
Prof.
Philip SAMBROOK (Australia) |
|
| 1000-1010 |
Souvenir
Presentation to Key Sponsors |
|
| 1010-1100 |
Poster
Viewing |
|
| 1100-1230 |
Concurrent
Symposia 4 |
|
| ¡@ |
CS7:
Lupus, antiphospholipid syndrome and the cardiovascular
system |
¡@ |
|
| |
Chairpersons:
Prof. Yi DONG (China) & Dr.
Man Choi WAN (Hong Kong)
|
|
| 1100-1130 |
CS7-1
- Basic mechanisms of atherosclerosis and the role of
the immune system |
Prof.
Bevra HAHN (USA) |
|
| 1130-1200 |
CS7-2
- New avenues in the antiphospholipid antibody syndrome |
Prof.
Yehuda SHOENFELD (Israel) |
|
| 1200-1230 |
CS7-3
- Antiphospholipid antibodies: from bench to bedside |
Prof.
Takao KOIKE (Japan) |
|
| ¡@ |
CS8:
Gouty arthritis |
¡@ |
|
| |
Chairpersons:
Dr. Chula RAJAPAKSE (New Zealand) &
Dr. Ronald F. TAN (Hong Kong)
|
|
| 1100-1130 |
CS8-1
- Genetics of Renal Urate transport in Gout |
Dr.
Tony MERRIMAN (New Zealand) |
|
| 1130-1200 |
CS8-2
- Pathophysiology of Gout and Imaging |
Dr.
JacquieHARPER (New Zealand) |
|
| 1200-1230 |
CS8-3
- Management of Gout |
Dr.
Lisa STAMP (New Zealand) |
|
| ¡@ |
BS4:
Dysregulation of immune system in autoimmunity |
¡@ |
|
| |
Chairpersons:
Dr. Liwei LU (Hong Kong) & Dr.
Eric Y T CHAN (Hong Kong) |
|
| 1100-1130 |
BS4-1
- Pathogenesis and Progression of Proliferative Lupus
Nephritis. Lessons Learned from Studies on NZM2328 and
its Congenic Lines |
Prof.
Shu Man FU (USA) |
|
| 1130-1200 |
BS4-2
- The role of dendritic cells in systemic lupus erythematosus |
Prof.
Chak Sing LAU (Hong Kong) |
|
| 1200-1230 |
BS4-3
- Follicular helper T cells: a new player in immune
tolerance |
Dr.
Di YU (Australia) |
|
| ¡@ |
PS2:
Use of biologics and SLE management update |
¡@ |
|
| |
Chairpersons:
Prof. S YOKOTA (Japan) & Dr.
T L LEE (Hong Kong)
|
|
| 1100-1130 |
PS2-1
- Recent advances in auto inflammatory Disease |
Prof.
Patricia WOO (UK) |
|
| 1130-1200 |
PS2-2
- Novel Lupus Nephritis Biomarkers |
Dr.
Hermine BRUNNER (USA) |
|
| 1200-1230 |
PS2-3
- Molecular intervention therapy: anti-IL-6 receptor monoclonal
antibody, Tocilizumab, for children with systemic juvenile
idiopathic arthritis
|
Prof.
Shumpei YOKOTA (Japan) |
|
| ¡@ |
Free
paper presentation 4
Chairpersons: Prof. Zhanguo LI
(China) & Prof. Ranjeny THOMAS (Australia)
|
|
| 1100-1110 |
FP4-1
- [0721] Annexin-1 regulates inflammation and glucocorticoid
sensitivity of rheumatoid synovial fibroblasts.
|
Y
JIA (China)
|
|
| 1110-1120 |
FP4-2
- [0049] Suppression of fibronectin fragment-activated
p38 pathway?by hyaluronan via its receptors in rheumatoid
arthritis chondrocytes
|
TA
YASUDA (Japan)
|
|
| 1120-1130 |
FP4-3
- [0877] The study of the role of a new type of nature
killer cells-NK-22 cells in the pathogenesis of rheumatoid
arthritis
|
JR
JIE REN (China)
|
|
| 1130-1140 |
FP4-4
- [0091] The SOX6 gene: evidence for shared genetic
susceptibility between schizophrenia and rheumatoid
arthritis in Caucasians
|
TR
MERRIMAN
( New Zealand)
|
|
| 1140-1150 |
FP4-5
- [0935] Molecular mechanism and new therapeutic targets
of rheumatoid arthritis
|
Ping
ZHU (China)
|
|
| 1150-1200 |
FP4-6
- [0289] Identification of autoantigen BiP-Derived HLA-DR4
epitope and its pathological roles in rheumatoid arthritis
|
H
SHODA (Japan)
|
|
| 1200-1210 |
FP4-7
- [0654] Altered microRNA expression profile with miR-146a
upregulation in CD4+ T cells from patients with rheumatoid
arthritis
|
JY
LI (China)
|
|
| 1210-1220
|
FP4-8
- [0404] HLA-DRB1 shared epitope as a genetic susceptibility
risk factor for different rheumatoid arthritis subgroups
in Malaysian population
|
CL
TOO (Sweden)
|
|
| 1220-1230 |
FP4-9
- [0685] Circulating dickkopf-1 and osteoprotegerin
in patients with early and longstanding rheumatoid arthritis
|
ZG
LI (China)
|
|
| 1230-1400 |
Lunch
Symposium (Sponsored by Janssen)
Chairperson: Dr. CC Mok (Hong Kong |
|
| 1230¡V1400 |
LS2-1
- Treating rheumatoid arthritis in the new decade ¡V
evidence, prospects and challenges |
Prof.
Josef S SMOLEN (Austria) |
|
| 1230-1400 |
Lunch
Symposium (Sponsored by MSD)
Challenges Managing Musculoskeletal Conditions: Opportunities
for Patients with Osteoporosis and Pain Associated with
Arthritic Diseases
Chairman: Prof. CS LAU (Hong Kong)
|
|
| 12:40-13:00 |
LS3-1
- Effects of Vitamin D on Patients
Suffering from Osteoporosis
|
Heike
BISCHOFF-FERRARI (Switzerland) |
|
| 13:00-13:20 |
LS3-2
- Pain in Osteoporosis:
An Underappreciated Phenomenon
|
Rick
ADACHI (Canada) |
|
| 13:20-13:45 |
LS3-3
- Multimodal Approach to Managing Pain
Associated with Ankylosing Spondylitis and Rheumatoid
Arthritis
|
Joachim
SIEPER (Germany) |
|
| 1400-1530 |
Concurrent
Symposia 5 |
|
| ¡@ |
CS9:
RA - Special issues on the safety of TNF blockers |
¡@ |
|
| |
Chairpersons:
Dr. Debashish DANDA (India) & Dr.
Daniel K H NG (Hong Kong)
|
|
| 1400-1430 |
CS9-1
- Prevention of latent TB reactivation in areas of high
TB burden |
Dr.
Chi Chiu LEUNG (Hong Kong) |
|
| 1430-1500 |
CS9-2
- Immune suppression and exacerbation of chronic hepatitis
B |
Prof.
Ching Lung LAI (Hong Kong) |
|
| 1500-1530 |
CS9-3
- Malignancy and non-TB, non-Hep B adverse reactions
in patients using TNF blockers |
Prof.
Zhanguo LI (China) |
|
| ¡@ |
CS10:
Imaging in rheumatology II |
¡@ |
|
| |
Chairpersons:
Brig. Chaturvedi VED (India) &
Dr. Jude S M WONG (Hong Kong)
|
|
| 1400-1430 |
CS10-1
- What concepts have we learned from modern imaging
of rheumatoid and osteoarthritis? |
Prof.
Philip CONAGHAN (UK) |
|
| 1430-1500 |
CS10-2
- Utility of MRI in LBP |
Prof.
James GRIFFITH (Hong Kong) |
|
| 1500-1530 |
CS10-3
- Interpretation of dual energy X-ray absorptiometry
results |
Dr.
Shing Kei CHEUNG (Hong Kong) |
|
| ¡@ |
BS5:
Pathogenesis of systemic lupus erythematosus |
¡@ |
|
| |
Chairpersons:
Dr. Eric Y T CHAN (Hong Kong) &
Dr. Temy Mo Yin MOK (Hong Kong)
|
|
| 1400-1430 |
BS5-1
- Novel cytokines in SLE |
Prof.
Peter E LIPSKY (USA) |
|
| 1430-1500 |
BS5-2
- T/B lymphocytic biomarkers in SLE patients |
Prof.
Xuan ZHANG (China) |
|
| 1500-1530 |
BS5-3
- A review of genetics of SLE in Asians |
Prof.
Sang-Cheol BAE (Korea) |
|
| ¡@ |
AHS2:
Bone health and osteoarthritis |
¡@ |
|
| |
Chairpersons:
Prof. Catherine BACKMAN (Canada) &
Mr. Anthony KWOK (Hong Kong) |
|
| 1400-1500 |
AHS2-1
- Energy conservation and joint protection for people
with arthritis: evidence based practice. |
Prof.
Catherine BACKMAN (Canada) |
|
| 1500-1510 |
AHS2-2
- The Prevalence of Vertebral Fractures in Asians with
Osteoporosis |
Mr.
Anthony Wai Leung KWOK (Hong Kong) |
|
| 1510-1520 |
AHS2-3
- The effects of whole body vibration therapy in older
adults, its implication for individuals with OA knee |
Dr.
Marco PANG (Hong Kong) |
|
| 1520-1530 |
AHS2-4
- [0195] Rheumatoid arthritis care in resource poor
settings : need for comprehensive ?public health policy
|
DS
PRAMOD (India)
|
|
| ¡@ |
Community
Oriented Program for the Control of Rheumatic Diseases(COPCORD
1) |
¡@ |
|
| |
Chairpersons:
Dr. Atiqul HAQ (Bangladesh) & Dr.
Tak Cheong CHEUNG (Hong Kong)
|
|
| 1400-1415 |
COPCORD
1-1-Effect of Ethnic Origin (Caucasians versus Turks)
on the Prevalence of Rheumatic Diseases: a WHO-ILAR
COPCORD Urban Study in Iran. |
Prof.
Fereydoun DAVATCHI (Iran) |
|
| 1415-1430 |
COPCORD
1-2 - Prevalence of Rheumatic musculoskeletal disorders
in a Rural population of South India .Kerala using the
WHO-ILAR COPCORD Bhigwan Model- a BJD India Initiative
|
Dr.
Asuma A. RAHIM (India) |
|
| 1430-1445 |
COPCORD
1-3- Burden of Rheumatic Musculoskeletal disorders in
Rural Manipur (North-East India): A WHO-ILAR COPCORD
Bhigwan model study |
Prof.
Romi SINGH (India) |
|
| 1445-1500 |
COPCORD
1-4- Rheumatic Diseases in Lebanon: a national study |
Prof.
Zeinab SLIM (Lebanon) |
|
| 1500-1515 |
COPCORD
1-5 -Epidemiology study of soft tissue rheumatism in
Shantou and Taiyuan, China |
Prof.
Qing Yu ZENG (China) |
|
| ¡@ |
Free
paper presentation 5
Chairpersons: Prof. Peter BROOKS (Australia)
& Dr. Carman HO (Hong Kong)
|
|
|
1400-1410 |
FP5-1
- [0096] Treatment of Kunxian capsule in rheumatoid
arthritis patients: a multi-center trial.
|
C
S LIN (China)
|
|
|
1410-1420 |
FP5-2
- [0147] The addition of another disease-modifying anti-rheumatic
drug, bucillamine, to methotrexate in place of infliximab
improves the rate of infliximab-free sustained remission
|
H
KAMEDA (Japan)
|
|
| 1420-1430 |
FP5-3
- [0245] Causes and predictors of death and prognosis
in familial Mediterranean fever in the colchicine era
|
Servet
AKAR (Turkey)
|
|
|
1430-1440 |
FP5-4
- [0262] Cost-effectiveness of celecoxib, nonselective
NSAID and NSAID with proton-pump inhibitor in patients
with rheumatoid arthritis in Korea
|
SJ
CHUNG (Korea)
|
|
|
1440-1450 |
FP5-5
- [0441] Clinical features and prognosis of patients
with autoimmune disease admitted to the medical intensive
care unit.
|
Q
WANG (China)
|
|
| 1450-1500 |
FP5-6
- [0509] The significance of Serum peptidylarginine
deiminase 4 in the pathogenesis of rheumatoid arthritis
|
L
QIAN (China)
|
|
| 1500-1510 |
FP5-7
- [0581] Serum cathepsin K levels of patients with rheumatoid
arthritis
correlation with radiological destruction
|
AI
ELZAWAWY (Egypt)
|
|
| 1510-1520 |
FP5-8
- [0710] Risk of tuberculosis in patients with rheumatoid
arthritis in Hong Kong- the role of TNF blockers in
an area of high tuberculosis burden
|
LS
TAM (Hong Kong)
|
|
| 1520-1530 |
FP5-9
- [0813] Synovial B lineage cell infiltrates are associated
with joint destruction of rheumatoid arthritis
|
Ying-qian
MO (China)
|
|
| 1530-1600 |
Coffee
Break |
|
| 1600-1730 |
Concurrent
Symposia 6 |
|
| ¡@ |
CS11:
Ankylosing spondylitis |
¡@ |
|
| |
Chairpersons:
Dr. Layla KAZKAZ (Syria) & Dr.
Ling Yin HO (Hong Kong)
|
|
| 1600-1630 |
CS11-1a
- What will prevent the progression of structural progression
in AS? |
Prof.
David Tak Yan YU (USA) |
|
| CS11-1b
- Can disease progression be arrested in AS or in RA? |
Prof.
James LOUIE (USA) |
|
| 1630-1700 |
CS11-2
- Sequential therapy of AS with anti-TNF and thalidomide |
Prof.
Feng HUANG (China) |
|
| 1700-1730 |
CS11-3
- Update on Enthesitis-related Arthritis, a subgroup
of Juvenile Idiopathic Arthritis |
Dr.
Tsz Leung LEE (Hong Kong) |
|
| ¡@ |
ES2:
Rheumatology pearls ¡V manuscript preparation and case
presentation |
¡@ |
|
| |
Chairpersons:
Dr. Ashok KUMAR (India) & Dr.
Moon Ho LEUNG (Hong Kong)
|
|
| 1600-1630 |
ES2-1
- Overcoming hurdles in preparing a manuscript: an editor's
perspective |
Dr.
Jennifer BUCKLAND (UK) |
|
| 1630-1640 |
ES2-2
- [0074] Complete heart block in a patient with Wegener
granulomatosis
|
MO
ZABIHIYEGANEH (Iran)
|
|
| 1640-1650 |
ES2-3
- [0191] Fibroblastic rheumatism: an easily misdiagnosed
clinical entity
|
Lanlan
JI (China)
|
|
|
1650-1700 |
ES2-4
- [0316] Etanercept-induced anti-synthetase syndrome
in patients with rheumatoid arthritis: case reports
and review of the literature
|
Y
ISHIKAWA (Japan)
|
|
| 1700-1710 |
ES2-5
- [0766] Two case reports of Churg Strauss Syndrome
presenting as progressive muscle weakness
|
ML
ROSALES (Philippines)
|
|
| 1710-1720 |
ES2-6
- [0825] Pauci-immune crescentic glomerulonephritis
in a patient with limited systemic sclerosis
|
PT
CHAN (Hong Kong)
|
|
| ¡@ |
BS6:
Mesenchymal stem cell |
¡@ |
|
| |
Chairpersons:
Prof. Ho-Youn KIM (Korea) & Prof.
Ronald LI (Hong Kong)
|
|
| 1600-1630 |
BS6-1
- Mesenchymal stem cell control of B cell |
Prof.
Lingyun SUN (China) |
|
| 1630-1700 |
BS6-2
- Therapeutic use of human embryonic/mesenchymal/induced
pluripotent stem cells: From the immunological perspective |
Prof.
Ronald LI (Hong Kong) |
|
| 1700-1730 |
BS6-3
- Chondrogenesis from mesenchymal stem cells |
Prof.
Gun-Il IM (Korea) |
|
| ¡@ |
BS7:
Genetics of rheumatic diseases |
¡@ |
|
| |
Chairpersons:
Prof. Sang-Cheol BAE (Korea) &
Prof. Jieruo GU (China)
|
|
| 1600-1630 |
BS7-1
- Genetics of systemic lupus erythematosus |
Prof.
Yu Lung LAU (Hong Kong) |
|
| 1630-1700 |
BS7-2
- Genome-wide association studies of rheumatoid arthritis
and the ethnic differences |
Prof.
Kazuhiko YAMAMOTO (Japan) |
|
| 1700-1730 |
BS7-3
- Geneticsof AS |
Prof.
Jieruo GU (China) |
|
| ¡@ |
COPCORD
2 |
¡@ |
|
| |
Chairpersons:
Prof. K M MAHENDRANATH (India) &
Dr. L S TAM (Hong Kong)
|
|
| 1600-1620 |
COPCORD
2-1 - Epidemiology of systemic lupus erythematosus in
Taiwan- National data from National Health Institute
of Taiwan. |
Dr.
Chung Tei CHOU (Taiwan) |
|
| 1620-1640 |
COPCORD
2-2 - Measuring the burden of rheumatic musculoskeletal
pain and disorders (RMSK) in India using WHO ILAR COPCORD
(community oriented program for control of rheumatic
diseases) Bhigwan model-A Bone and Joint Decade (BJD)
India initiative |
Prof.
Arvind CHOPRA (India) |
|
| 1640-1700 |
COPCORD
2-3 - Identification of risk factors for knee osteoarthritis |
Dr.
Nazrul ISLAM (Bangladesh) |
|
| 1700-1720¡@ |
COPCORD
2-4 - APLAR-COPCORD Questionnaire for Identification
of Risk Factors for Non-specific Low Back Pain
|
Prof.
Syed Atiqul HAQ (Bangladesh) |
|
| ¡@ |
Free
paper presentation 6
Chairpersons: Prof. Fengchun ZHANG
China) & Prof. Edmund K LI (Hong
Kong)
¡@ |
|
| 1600-1610 |
FP6-1
- [0032] Abatacept demonstrated?long-term safety and
efficacy in active RA patients who showed inadequate
response to methotrexate: an analysis of the Japanese
phase III open-label, long-term extension trial
|
Y
TANAKA (Japan)
|
|
| 1610-1620 |
FP6-2
- [0073] Vitamin D levels and bone mineral density response
to bone active therapy in pre-menopausal malaysian systemic
lupus erythematosus patients on corticosteroids |
SS
YEAP (Malaysia)
|
|
| 1620-1630 |
FP6-3
- [0142] Response, remission and flare during early
treatment of rheumatoid arthritis with infliximab: the
REMARK study
|
N
VASTESAEGER (Sweden)
|
|
| 1630-1640 |
FP6-4
- [0143] Odanacatib treatment of postmenopausal women
with low bone mineral density: 3-year continued therapy
and resolution of effect
|
R
ADACHI (USA)
|
|
| 1640-1650 |
FP6-5
- [0202] Long-term efficacy of tocilizumab in patients
with rheumatoid arthritis (RA) treated up to 3.5 years
|
G
JONES (Australia)
|
|
| 1650-1700 |
FP6-6
- [0205] Tocilizumab inhibits radiographic progression
and reduces disease activity continuously over time
in patients with rheumatoid arthritis (RA)
|
ZG
LI (China)
|
|
| 1700-1710 |
FP6-7
- [0357] CRP association with clinical response to infliximab:
the REMARK study
|
J
SMOLEN (Netherlands)
|
|
| 1710-1720 |
FP6-8
- [0458] Achieving HAQ remission in rheumatoid arthritis
with the combination of infliximab and methotrexate
|
PY
SHANE (USA)
|
|
| 1720-1730 |
FP6-9
- [0824] Disease remission is achieved within two years
in over half of methotrexate naive patients with early
erosive rheumatoid arthritis (RA) treated with abatacept
plus MTX: ?Results from the AGREE trial
|
J-C
BECKER (USA)
|
|
| 1830-2130 |
Congress
Dinner (By invitation or
by ticket) |
|
| |
|
|
| Day
4, 14 July (Wednesday) |
|
| 0830-1000 |
Plenary
Session 3 : Systemic Lupus Erythematosus (SLE) |
¡@ |
|
| |
Chairpersons:
Prof. Shunle CHEN (China) &
Dr. Kee Lam WONG (Hong Kong)
|
|
| 0830-0900 |
Plenary
3-1 - Therapies of SLE: what have we achieved and what
are our future targets? |
Prof.
Michelle A PETRI (USA) |
|
| 0900-0930 |
Plenary
3-2 - Update on B cell therapies in SLE |
Prof.
David ISENBERG (UK) |
|
| 0930-1000 |
Plenary
3-3 - Type I interferon and lupus |
Prof.
Nan SHEN (China) |
|
| 1000-1100 |
Poster
Viewing |
|
| 1100-1230 |
Concurrent
Symposia 7 |
|
| ¡@ |
CS12:
Biologic therapies in RA |
¡@ |
|
| |
Chairpersons:
Prof. Kusuki NISHIOKA (Japan) &
Dr. Gavin Ka Wing LEE (Hong Kong)
|
|
| 1100-1130 |
CS12-1
- Biological Therapies of Rheumatoid Arthritis Beyond
TNF-Bloclade |
Prof.
Josef S SMOLEN (Austria) |
|
| 1130-1200 |
CS12-2
- Biologic therapies in the Asian Pacific region |
Prof.
Chak Sing LAU (Hong Kong) |
|
| 1200-1230 |
CS12-3
- Biology of IL-6 and its blockade in clinical practice |
Prof.
Norihiro NISHIMOTO (Japan) |
|
| ¡@ |
CS13:
Psoriatic arthritis |
¡@ |
|
| |
Chairpersons:
Dr. Shue-Fen LUO (Taiwan) & Dr.
Lucia CHAU (Hong Kong)
|
|
| 1100-1130 |
CS13-1
-Targeted therapies in psoriatic arthritis and future
directions |
Prof.
Ernest CHOY (UK) |
|
| 1130-1200 |
CS13-2
- Outcome measures in Psoriatic Arthritis |
Dr.
Ying Ying LEUNG (Hong Kong) |
|
| 1200-1230 |
CS13-3
- Subclinical atherosclerosis in PSA |
Dr.
Lai Shan TAM (Hong Kong) |
|
| ¡@ |
BS8:
Th17 and inflammatory arthritis |
¡@ |
|
| |
Chairpersons:
Prof. Ho-Youn KIM (Korea) &
Prof. Eddy F Y LIEW (UK)
|
|
| 1100-1130 |
BS8-1
- The role of Th1 and Th17 cells in joint destruction |
Prof.
Wim B VAN DEN BERG (The Netherlands) |
|
| 1130-1200 |
BS8-2
- Th17 in rheumatoid arthritis |
Prof.
Pierre MIOSSEC (France) |
|
| 1200-1230 |
BS8-3
- Regulation and function of novel T cell subsets in
autoimmunity |
Prof.
Chen DONG (US) |
|
| ¡@ |
PS3:
Autoinflammatory diseases and novel lupus nephritis
markers |
¡@ |
|
| |
Chairpersons:
Prof. Xiaohu HE (China) & Dr. Joannie
HUI (Hong Kong)
|
|
| 1100-1130 |
PS3-1-
Update on Management of childhood onset SLE |
Dr.
Hermine BRUNNER (USA) |
|
| 1130-1200 |
PS3-2
- Is there still a role for haematopoietic stem cell
transplantation for autoimmune diseases? |
Dr.
Tsz Leung LEE(Hong Kong) |
|
| 1200-1210 |
PS3-3
- [0402] Limitations (rheumatoid factor,HLA B27,undifferentiated
arthritis, economics)of the ILAR classification system
(Edmonton 2001) for juvenile idiopathic arthritis (JIA):An
Indian community cohort study
|
Arvind
CHOPRA (India)
|
|
|
1210-1220 |
PS3-4
- [0854] Clinical phenotype and CARD15 gene mutation
with blau syndrome in Chinese children and their parents
|
CF
LI (China)
|
|
|
1220-1230 |
PS3-5-
[0255] Intensive therapy of vasculitises at children
|
G.M.
SAATOVA (Kyrgyzstan) |
|
| ¡@ |
Free
paper presentation 7
Chairpersons: Prof. David Tak Yan YU
(USA) & Prof. Yehuda SHOENFELD
(Israel) |
|
| 1100-1110 |
FP7-1
- [0463] Association study of STAT4, IRF7, C1q and IKZF1
polymorphisms with Systemic Lupus Erythematosus in Chinese
Han population
|
Ping
LI (China)
|
|
| 1110-1120 |
FP7-2
- [0006] Change in plamsa level of soluble E- selectin
and+A561C polymorphisms in children with Kawasaki disease
|
G
CHEN (China)
|
|
| 1120-1130 |
FP7-3
- [0377] Immune response to outer membrane protein of
enterobacteriaceae in patients with enthesitis related
arthritis
|
YP
SINGH (India)
|
|
| 1130-1140 |
FP7-4
- [0817] Therapeutic effect of IL-18 gene delivery on
murine collagen - induced arthritis.
|
Y
LI (China)
|
|
| 1140-1150 |
FP7-5
- [0318] Post-transcriptional regulation of IL-6 production
by Zc3h12a in fibroblast-like?synovial cells
|
KT
KOGA/TOMOHIRO (Japan)
|
|
|
1150-1200 |
FP7-6
- [0026] Association of MHC genes and spinal fusion
in patients with ankylosing spondylitis (AS)
|
WS
CHEN (Taiwan)
|
|
|
1200-1210 |
FP7-7
- [0653] Parthenolide, a natural inhibitor of Nuclear
Factor-kappaB, inhibits human chondrocytes degradation
in vitro and improved symptoms of patients with osteoarthritis
in vivo.?
|
T
IKAWA (Japan)
|
|
| 1210-1220 |
FP7-8
- [0459] Significance of high Osteoprotegerin (OPG)
Expression in synovial tissue of patients with Ankylosing
Spondylitis (AS)
|
W
ZHAO (China)
|
|
|
1220-1230 |
FP7-9
- [0196] Common MEFV mutation analysis in 36 Iranian
patients with Familial Mediterranean Fever (clinical
and demographic significance)
|
B
GHAVIDEL PARSA (Iran)
|
|
| 1230-1400 |
Lunch
Symposium (Sponsored by Abbott)
Treat Today for Tomorrow
Chairperson: Prof. CS LAU (Hong Kong)
|
|
| 1245-1315 |
LS4-1
- Assessing the Performance of Rheumatoid Arthritis
Therapies |
Prof.
Ferdinand C BREEDVELD (The Netherlands) |
|
| 1315-1345 |
LS4-2
- Spondyloarthritis: Controversies and Challenges in
Treatment |
Prof.
Walter MAKSYMOWYCH |
|
| |
Lunch
Symposium (Sponsored by GSK) |
|
|
| 1230-1400 |
|
|
|
| |
Lunch
Symposium (Sponsored by Rottapharm Madaus)
Chairperson:
|
|
|
| 1230-1400 |
LS6-1
- The update of microcrystalline glucosamine on treatment
of OA |
Prof.
JY REGINSTER |
|
| 1400-1530 |
Concurrent
Symposia 8 |
¡@ |
|
| ¡@ |
CS14:
SLE-morbidities and mortality |
¡@ |
|
| |
Chairpersons:
Dr. U R K RAO (India) & Dr.
Ronald M L YIP (Hong Kong)
|
|
| 1400-1430 |
CS14-1
- Epidemiology and survival of systemic lupus erythematosus
in Hong Kong Chinese |
Dr.
Chi Chiu MOK (Hong Kong) |
|
| 1430-1500 |
CS14-2
- Infections in systemic lupus erythematosus |
Dr.
Sandra V NAVARRA (Phillippines) |
|
| 1500-1530 |
CS14-3
- Preventing morbidity in CNS lupus |
Dr.
Hwee Siew HOWE (Singapore) |
|
| ¡@ |
CS15:
Osteoporosis |
¡@ |
|
| |
Chairpersons:
Prof. Ahmad MIR AHMAD (Pakistan) &
Dr. Catherine YUEN (Hong Kong)
|
|
| 1400-1430 |
CS15-1
- What is the risk of osteoporosis and fracture associated
with different inflammatory musculoskeletal conditions
¡V the epidemiological data |
Prof.
Anthony D WOOLF (UK) |
|
| 1430-1500 |
CS15-2
- Fracture prevention in men |
Prof.
Philip SAMBROOK (Australia) |
|
| 1500-1530 |
CS15-3
- Guideline for the monitoring of bone turnover, bone
mineral density and treatment in postmenopausal osteoporosis |
Prof.
Jean Yves REGINSTER (Belgium) |
|
| ¡@ |
BS9:
Novel targets in rheumatic diseases |
¡@ |
|
| |
Chairpersons:
Prof. Nan SHEN (China) & Prof.
Chak Sing LAU (Hong Kong)
|
|
| 1400-1430 |
BS9-1
- Epigenetic targets in the pathogenesis of RA |
Prof.
Steffen GAY (Switzerland) |
|
| 1430-1500 |
BS9-2
- The inhibitory effect of miRNA in rheumatoid arthritis |
Prof.
Zhanguo LI (China) |
|
| 1500-1530 |
BS9-3
- Clinical development and trials of DC therapy for
rheumatoid arthritis |
Prof.
Ranjeny THOMAS (Australia) |
|
| ¡@ |
AHS3:
Management model for arthritis-related pain |
¡@ |
|
| |
Chairpersons:
Prof. Kim BENNELL (Australia) &
Mr. Peter POON (Hong Kong) |
|
| 1400-1500 |
AHS3-1
- Improving the patient experience of healthcare. |
Mrs.
Susan OLIVER (UK) |
|
| 1500-1510 |
AHS3-2
- A transitional care model for supporting clients returning
home with chronic illness |
Prof.
Frances WONG (Hong Kong) |
|
| 1510-1520 |
AHS3-3
- Tele- monitoring model for community dwelling with
osteoarthritis knee |
Dr.
Amy S N FU (Hong Kong) |
|
| 1520-1530 |
AHS3-4
- What we have learned from the Arthritis Self-management
Program? |
Ms.
Wai-Ping Phyllis CHAU (Hong Kong) |
|
| ¡@ |
Free
paper presentation 8
Chairpersons:
Prof. John EDMONDS (Australia) &
Dr. Ying Ying LEUNG (Hong Kong)¡@ |
|
| 1400-1410 |
FP8-1
- [0076] Correlation between family APGAR scores and
health related quality of life of Filipino elderly patients
with knee osteoarthritis
|
AT
LIM (Philippines)
|
|
| 1410-1420 |
FP8-2
- [0093] Mesenchymal stem cell transplantation for the
treatment of knee osteoarthritis. Preliminary report
of four patients
|
F
DAVATCHI (Iran)
|
|
| 1420-1430 |
FP8-3
- [0164] Preliminary assessment of the safety and efficacy
of tanezumab (PF-04383119) in Japanese patients with
moderate to severe osteoarthritis of the knee
|
S
ARAKI (UK)
|
|
| 1430-1440 |
FP8-4
- [0270] Etanercept is significantly more effective
than sulfasalazine in patients with ankylosing spondylitis
|
AS
KOENIG (USA)
|
|
| 1440-1450 |
FP8-5
- [0284] Effects of HYLAN G-F 20 [Synvisc R] supplementation
on cartilage preservation in osteoarthritis of the knee:
a two-year, single -blind clinical trial
|
YY
WANG (Australia)
|
|
| 1450-1500 |
FP8-6
- [0783] Geographical differences in the determinants
of symptomatic knee osteoarthritis in Lebanon: a population-based
case control study using incident cases.
|
MC
CHAAYA (Lebanon)
|
|
| 1500-1510 |
FP8-7
- [0822] Degradation of Type II Collagen ?in knee osteoarthritis
|
Najirman
NAJIRMAN (Indonesia)
|
|
| 1510-1520 |
FP8-8
- [0866] Efficacy and safety of ultrasound-guided injection
in treatment of ankylosing spondylitis patients with
Achilles enthesitis
|
ZT
LIAO (China)
|
|
|
1520-1530 |
FP8-9
- [0896] Giant Cell Arteritis and Mortality: results
of a population-based cohort study.
|
CL
HILL (Australia)
|
|
| 1530-1600 |
Coffee
Break |
|
| 1600-1730 |
Concurrent
Symposia 9 |
|
| ¡@ |
CS16:
Osteoarthritis |
¡@ |
|
| |
Chairpersons:
Dr. Buyun YU (China) &
Dr. Kai Yiu MA (Hong Kong)
|
|
| 1600-1630 |
CS16-1
- A Comparison of Modern Osteoarthritis Guidelines |
Prof.
Philip CONAGHAN (UK) |
|
| 1630-1700 |
CS16-2 - Health Related Quality of Life in Osteoarthritis |
Prof.
Julian THUMBOO (Singapore) |
|
| 1700-1730 |
CS16-3
- A clinical model of care for OA for the hip and knee |
Dr.
Keith LIM (Australia) |
|
| ¡@ |
CS17:
Orthopedics |
¡@ |
|
| |
Chairpersons:
Dr. Wai Sin CHAN (Macau) & Prof.
Ikuo NAGAYA (Japan)
|
|
| 1600-1630 |
CS17-1
- The Bone and Joint Decade 2010 and beyond ¡V the impact
of translational research in musculoskeletal disorders |
Prof.
Kai Ming CHAN (Hong Kong) |
|
| 1630-1700 |
CS17-2
- Orthopaedic management of peripheral arthritis |
Prof.
Peter Kwong Yuen CHIU (Hong Kong) |
|
| 1700-1730 |
CS17-3
- How has geneticsaltered our understanding on low back
pain: implications for its treatment |
Prof.
Kenneth CHEUNG (Hong Kong) |
|
| ¡@ |
BS10:
Pathogenesis of neuropsychiatric lupus |
¡@ |
|
| |
Chairpersons:
Prof. K Y FONG (Singapore) &
Dr. Kong Chiu WONG (Hong Kong)
|
|
| 1600-1630 |
BS10-1
- Pathogenesis of NPSLE |
Dr.
Temy Mo Yin MOK (Hong Kong) |
|
| 1630-1700 |
BS10-2
- Brain Reactive Autoantibodies in SLE |
Prof.
K Y FONG (Singapore) |
|
| 1700-1730 |
BS10-3
- The story of the CNS involvement in SLE |
Prof.
Yehuda SHOENFELD (Israel) |
|
| ¡@ |
Free
paper presentation 9
Chairperson: Prof. Yi DONG
(China) & Dr. Woon Leung NG (Hong
Kong)
|
|
| 1600-1610 |
FP9-1
- [0036] Efficacy of alendronate in the treatment of
steroid associated osteonecrosis of the knee.A prospective
open label study
|
kensuke
KUME (Japan)
|
|
|
1610-1620 |
FP9-2
- [0174] Efficacy of canakinumab (ACZ885) compared to
triamcinolone acetonide for treatment of acute flares
and prevention of recurrent flares in gouty arthritis
patients
|
A
SO (Switzerland)
|
|
|
1620-1630 |
FP9-3
- [0226] Higher mortality risk in gout subjects in comparison
with national population
|
HC
CHANG (Taiwan)
|
|
| 1630-1640 |
FP9-4
- [0323] Nailfold capillaroscopy by digital microscope
in Indian population with connective tissue disorders
|
DS
BHAKUNI (India)
|
|
| 1640-1650 |
FP9-5
- [0328] Relationship of ultrasonographic findings with
synovial angiogenesis modulators indifferent forms of
knee arthritidies
|
Hakan
ERDEM (Turkey)
|
|
| 1650-1700 |
FP9-6
- [0395] Diagnostic accuracy of new criteria for rheumatoid
arthritis.
|
Ryoko
UESATO (Japan)
|
|
| 1700-1710 |
FP9-7
- [0590] Hyperuricemia and accelerated reduction in
renalFunction
|
CF
KUO (Taiwan)
|
|
|
1710-1720 |
FP9-8
- [0592] Nonlinear relationship between serum uric acid
level and all-cause and cardiovascular mortality
|
CF
KUO (Taiwan)
|
|
|
1720-1730 |
FP9-9
- [0630] Canakinumab (ACZ885) vs. colchicine in the
prevention of flares in gout patients initiating allopurinol
therapy
|
A
SO (Switzerland)
|
|
| |
|
| Day
5, 15 July (Thursday) |
|
| 0830-1000 |
Concurrent
Symposia 10 |
|
| ¡@ |
CS18:
Miscellaneous rheumatic diseases |
¡@ |
|
| |
Chairpersons:
Prof. Kevin PILE (Australia) &
Dr. Sandy TANG (Hong Kong)
|
|
| 0830-0900 |
CS18-1
- Sjogren's syndrome-Current developments |
Prof.
Rohini HANDA (India) |
|
| 0900-0930 |
CS18-2
- Advances in the treatment of fibromyalgia |
Prof.
Ernest CHOY (UK) |
|
| ¡@ |
CS19:
Crystal arthropathies-miscellaneous |
¡@ |
|
| |
Chairperson:
Dr. Virginia LAO (Hong Kong) & Dr.
Anita LIM (Singapore)
|
|
| 0830-0900 |
CS19-1
- The Update Mechanisms of MSU-mediated Inflammation |
Prof.
Hsiao Yi LIN (Taiwan) |
|
| 0900-0930 |
CS19-
2 - Management of CPPD arthritis |
Prof.
Alexander Kai Lik SO (Switzerland) |
|
| ¡@ |
BS11:
Osteoimmunology |
¡@ |
|
| |
Chairpersons:
Prof. Lingyun SUN (China) & Prof.
Hiroshi TAKAYANAGI (Japan)
|
|
| 0830-0900 |
BS11-1
- Bone destruction in arthritis |
Prof.
Hiroshi TAKAYANAGI (Japan) |
|
| 0900-0930 |
BS11-2
- Cytokine regulation of osteoclastogenesis |
Prof.
Matthew GILLESPIE (Australia) |
|
| 0930-1000 |
BS11-3
- Stem cell mobilization by osteoclast |
Prof.
Tsvee LAPIDOT (Israel) |
|
| ¡@ |
BS12:
Pathogenesis of other rheumatic diseases |
¡@ |
|
| |
Chairperson:
Prof. Dae-Hyun YOO (Korea) &
Dr. Chun Kwok WONG (Hong Kong)
|
|
| 0830-0900 |
BS12-1
- Dysregulated B cell signaling in systemic sclerosis:
a potential therapeutic target |
Prof.
Manabu FUJIMOTO (Japan) |
|
| 0900-0930 |
BS12-2
- Noble advance in rheumatology
by Asian rheumatologist
¢wCurrent novel achievement in rheumatology
|
Dr.
Yoshihisa YAMANO (Japan) |
|
| 0930-1000 |
BS12-3
- Pathogenesis of Adult onset still disease |
Prof.
Dae-Hyun YOO (Korea) |
|
| 1000-1030 |
Coffee
Break |
|
| 1030-1200 |
Plenary
Session 4 : Ankylosing Spondylitis |
¡@ |
|
| |
Chairpersons:
Prof. Peter BROOKS (Australia) &
Dr. Ka Ho CHAN (Hong Kong)
|
|
| 1030-1100 |
Plenary
4-1 - Immunopathogenesis of Ankylosing Spondyloarthritis |
Prof.
Chung Tei CHOU (Taiwan) |
|
| 1100-1130 |
Plenary
4-2 - Classification criteria for AS: what is new? |
Prof.
David Tak Yan YU (USA) |
|
| 1130-1200 |
Plenary
4-3 - Update on the novel therapies of AS |
Prof.
Edmund Kwok Ming LI (Hong Kong) |
|
| ¡@ |
Closing
Ceremony |
|
